Navivumab

Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2[1].

Product Specifications

CAS Number

1443004-16-7

Product Name Alternative

CT-P23

UNSPSC

12352203

Target

Influenza Virus

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/navivumab.html

Purity

99.10

Solubility

10 mM in DMSO

Smiles

[Navivumab]

Molecular Weight

(146.6 kDa)

References & Citations

[1]Beigel JH. Polyclonal and monoclonal antibodies for the treatment of influenza. Curr Opin Infect Dis. 2018 Dec;31 (6) :527-534.

Shipping Conditions

Dry Ice

Storage Conditions

Store at -80°C for 2 years

Scientific Category

Inhibitory Antibodies

Clinical Information

No Development Reported

Available Sizes

More Discoveries

Explore Other Products

Browse additional items from our catalog

9000-100 100 Plates

Brilliant Sodium Express - No wash sodium assay kit

View Details

TA368111 100 µL

Solute carrier family 22 member 18 (SLC22A18) Rabbit Polyclonal Antibody

View Details

TA502316BM 100 µL

RDH14 Mouse Monoclonal Antibody (HRP conjugated) [Clone ID: OTI3E1]

View Details

MR215096L3V 200 µL

Parp10 (NM_001163575) Mouse Tagged ORF Clone Lentiviral Particle

View Details

37234106 1 µg

POPDC2 AAV Vector (Rat) (CMV)

View Details

EF019360 96 Tests

Rat Sgpl1 ELISA Kit

View Details